



# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/431,546	10/29/1999	NICHOLAS P. EVERETT	INTERLINK-3.	8843

7590 01/13/2005  
WOMBLE, CARLYLE, SANDRIDGE & RICE, PLLC  
Post Office Box 7037  
Atlanta, GA 30357

EXAMINER

MCGARRY, SEAN

ART UNIT PAPER NUMBER

1635

DATE MAILED: 01/13/2005

Please find below and/or attached an Office communication concerning this application or proceeding.

<b>Office Action Summary</b>	<b>Applicati n No.</b>	<b>Applicant(s)</b>	
	09/431,546	EVERETT ET AL.	
	<b>Examiner</b>	<b>Art Unit</b>	
	Sean R McGarry	1635	

**-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --**  
**Period for Reply**

**A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.**

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

#### Status

- 1) ☒ Responsive to communication(s) filed on 08 March 2004.
- 2a) ☒ This action is **FINAL**.                      2b) ☐ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

#### Disposition of Claims

- 4) ☒ Claim(s) 1-13, 18-24 and 36-45 is/are pending in the application.
- 4a) Of the above claim(s) \_\_\_\_\_ is/are withdrawn from consideration.
- 5) ☐ Claim(s) \_\_\_\_\_ is/are allowed.
- 6) ☒ Claim(s) 1-13, 18-24, and 36-45 is/are rejected.
- 7) ☐ Claim(s) \_\_\_\_\_ is/are objected to.
- 8) ☐ Claim(s) \_\_\_\_\_ are subject to restriction and/or election requirement.

#### Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on \_\_\_\_\_ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.  
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).  
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

#### Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All    b) ☐ Some \*    c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
  2. ☐ Certified copies of the priority documents have been received in Application No. \_\_\_\_\_.
  3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).
- \* See the attached detailed Office action for a list of the certified copies not received.

#### Attachment(s)

- |   |   |
|---|---|
| 1) <input type="checkbox"/> Notice of References Cited (PTO-892)                        | 4) <input type="checkbox"/> Interview Summary (PTO-413)                     |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948)    | Paper No(s)/Mail Date. _____  |
| 3) <input type="checkbox"/> Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08) | 5) <input type="checkbox"/> Notice of Informal Patent Application (PTO-152) |
| Paper No(s)/Mail Date _____   | 6) <input type="checkbox"/> Other: _____                                    |

### DETAILED ACTION

The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

Claims 1-13, 18-24 and 36-45 remain rejected under 35 U.S.C. 112, first paragraph, as containing subject matter which was not described in the specification in such a way as to enable one skilled in the art to which it pertains, or with which it is most nearly connected, to make and/or use the invention. The specification is enabled for the scope of invention wherein a Rev4 peptide is administered externally to a plant, but not for the full scope claimed.

The instant specification teaches chemical synthesis of Rev4, Indolicidin, Ser-Rev4, Rev4-C-Terminal fusion, Indolicidin F, and Indolicidin F-P (amide) in Examples 1-6. The specification discloses in Example 8, the stability of Rev4 to proteases in whole cell extract. Example 9 discloses that Rev4 can "confer on Magainin 2 a stability" in whole cell extracts. Example 10 discloses that REV4 protects casein from commercial proteases in *in vitro* assays. In example 13 Rev4-related peptides which contained amino acid extensions on either the n-terminus or C-terminus (SEQ ID NO:s 5 and 6) were shown to have protease inhibiting properties while those peptides related to indolicidin had no protective effect. The specification then teaches one in the art how to make transgenic plants that express Rev4. The specification then teaches that such (Rev4 transformants) transgenic plants have increased resistance to pathogens.

The specification does not show any conferring of resistance of a protease to any specific protein via the expression from a plant transformed with a non-native DNA expressing Rev4, indolicidin, or a functional equivalent. The specification does not show that transgenic plants comprising a transgenic Rev4 confers to a protein any resistance to a protease when the protein is applied to the plant or expressed by the plant. Furthermore the invention is not limited to peptides of REV4 but includes transgenic plants expressing nucleic acids that comprises Rev4. It is not clear from the specification what the properties proteins or peptide expressed therefrom may have.

The instant specification has not shown by example the protection of proteins applied to a plant or plant part by the *expression* of a Rev4 or indolicidin based peptide on or by the plant. Applicant appear to admit, at page 2 for example, and Mourgues et al [TIBTECH Vol. 16:203-210, 5/98] appear to assert, that the expression of exogenous protein in plant do not typically have the expected properties. Applicant has shown that proteins mixed in an in vitro environment, apparently devoid of any other plant material, were protected, but it is unclear how such an example correlates to the protection of a protein in a plant or plant part where the biological environment is very different than that where the specific examples were tested and further how it might correspond to the expression of a Rev4 in a plant to act on a protein applied externally to a plant. An intact plant is most compartmentalized and the artificial conditions used in the instant examples, of course is not. An intact plant is a dynamic environment with many protein interactions, for example, where the artificial conditions used in the instant examples is static. A plant environment contains many variable which differ from plant to plant, from

Art Unit: 1635

plant part to plant part, from plant tissue to tissue, and from cell to cell, for example.

The example provided does not account for, what concentrations would need be expressed in a plant to confer protection to a particular peptide, and how does that peptide find that specific protein desired to be protected from all those in the plant environment, for example. Will the expressed protein protect all proteins in a plant, even those that need to be degraded for plant viability?

Since the art is unpredictable, the specification does not provide adequate guidance, and the specification fails to provide examples that correlate with the routine practice of the invention in view of the teachings of the specification, and since one in the art would need to engage in undue trial and error experimentation to overcome the concerns above to practice the instant invention, the instant invention is not supported by an enabling specification.

Applicant's arguments filed 3/8/04 have been fully considered but they are not persuasive. It is agreed that the conditions of the in vitro conditions of the examples would correlate to the action on a plant surface, for example, but the remaining scope of the invention is maintained for the reasons of record. The amendments provided do not overcome the rejection of record since one in the art would still be led to perform undue trial and error experimentation to determine methodologies and peptide composition for the use a protease inhibitor in an in vivo environment (ie inside or expressed from a plant). The amendments provide clarity to the various modes of action encompassed

Art Unit: 1635

within the claims, but do not necessarily address the concerns set forth in the rejection of record. The rejection is maintained for the same reasons of record.

**THIS ACTION IS MADE FINAL.** Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).


A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Sean R McGarry whose telephone number is (571) 272-0761. The examiner can normally be reached on M-Th (6:00-4:30).

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, John LeGuyader can be reached on (571) 272-0760. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Art Unit: 1635

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).



Sean R McGarry  
Primary Examiner  
Art Unit 1635

SRM